Company Encyclopedia
View More
name
Apyx Medical
APYX.US
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market.
1.407 T
APYX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking125/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-172.18%E
    • Profit Margin-30.35%E
    • Gross Margin64.43%A
  • Growth ScoreC
    • Revenue YoY-1.32%D
    • Net Profit YoY48.88%B
    • Total Assets YoY-5.53%D
    • Net Assets YoY-45.70%E
  • Cash ScoreD
    • Cash Flow Margin-329.45%D
    • OCF YoY-1.32%D
  • Operating ScoreB
    • Turnover0.81B
  • Debt ScoreE
    • Gearing Ratio89.40%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story

    Apyx Medical Corporation's shares have surged 38% in the last month, contributing to a 228% annual gain. Despite this, its price-to-sales ratio of 3.2x is close to the industry median of 3.1x. The company's recent revenue decline contrasts with industry growth, but analysts forecast a 13% annual growth for the next three years, outpacing the industry's 9.2%. Some investors remain skeptical, keeping the P/S ratio moderate. The market may be pricing in potential risks, despite the positive growth outlook.

    Simplywall·
    US
    APYX
    +0.75%
    Simplywall·
    US
    APYX
    +0.75%

    Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock

    Apyx Medical Corporation announced the pricing of its $10 million public offering of 2,762,431 shares at $3.62 per share. Lucid Capital Markets is the sole book-running manager. The offering is expected to close on November 19, 2025, with proceeds used for working capital and general corporate purposes. The offering is made under a shelf registration statement filed with the SEC. A 45-day option allows the purchase of an additional 414,365 shares. This announcement does not constitute an offer to sell securities.

    fidelity·
    US
    APYX
    +0.75%
    fidelity·
    US
    APYX
    +0.75%

    Apyx Medical Corporation Announces Proposed Public Offering of Common Stock

    CLEARWATER Fla., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Apyx Medical Corporation ( Nasdaq: APYX ) ( the "Company" or "Apyx Medical" ) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ ( AYON ) , today announced that it is commencing an ...

    GlobeNewswire·
    US
    APYX
    +0.75%
    GlobeNewswire·
    US
    APYX
    +0.75%

    Apyx Medical shares are trading lower after the company announced a public offering.

    benzinga_article·
    US
    APYX
    +0.75%
    benzinga_article·
    US
    APYX
    +0.75%

    Apyx Medical shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY2025 sales guidance.

    benzinga_article·
    US
    APYX
    +0.75%
    benzinga_article·
    US
    APYX
    +0.75%
    © 2025 Longbridge｜Disclaimer